Voting Rights and Shares Capital of the Company
Nanobiotix (Nasdaq: NBTX) published its voting rights and shares capital figures as of March 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nanobiotix (Nasdaq: NBTX) published its voting rights and shares capital figures as of March 31, 2026. The company reports 48,517,630 shares outstanding and total voting rights of 50,165,132 (theoretical) and 50,143,014 (exercisable).
Listings: Euronext Paris (Compartment B) and Nasdaq. ISIN: FR0011341205.
Details
News Market Reaction – NBTX
On Apr 8, the first trading day after this news, NBTX closed 2.22% above the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- Shares outstanding
- 48,517,630
- Nanobiotix share capital as of March 31, 2026
- Theoretical voting rights
- 50,165,132
- Total voting rights, theoretical, March 31, 2026
- Exercisable voting rights
- 50,143,014
- Total voting rights, exercisable, March 31, 2026
Historical Context
-
Improved 2025 financials and clinical progress, narrower net loss and solid cash.
-
Phase 2 lung cancer data with acceptable safety and strong initial efficacy metrics.
-
Announcement of timing for Q4 and full-year 2025 results and conference call.
-
Company denied any ongoing takeover process and corrected media speculation.
-
Disclosure of shares outstanding and theoretical versus exercisable voting rights.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
isin code financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, April 07, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| March 31, 2026 | 48,517,630 | 50,165,132 | 50,143,014 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).
Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachment
- 2026-04-07 -- NBTX -- Voting Rights & Shares Capital -- FINAL
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.